Erik Tucker

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Antibody Therapeutics. Top assignees: Oregon Health & Science University, Vanderbilt University, Bayer Pharma Aktiengesellschaft. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Tucker. Retrieved from https://idiyas.com/inventor/erik-tucker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 118(Granted Patents)

Company Filing History:

11 out of 526

Oregon Health & Science University

patents

8 out of 1,223

Vanderbilt University

patents

5 out of 387

Bayer Pharma Aktiengesellschaft

The United States Government as Represented by the Department of Veterans Affairs

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Thrombopoietin

Factor XII Antibody

Coagulation Factor XI

Monoclonal Antibodies

Inflammatory Diseases

Autoimmune Diseases

Nucleic Acids

Polynucleotides

Therapeutic Antibodies

Binding Affinity

Methods of Use

Antibody Engineering

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12496311 - METHODS FOR SAFELY REDUCING THROMBOPOIETIN (2025-12-16),

2. 12134657 - Therapeutic factor XII antibody (2024-11-05),

3. 11046783 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2021-06-29),

4. 10654941 - Antibodies against factor XI and uses thereof (2020-05-19),

5. 10577428 - Anti-factor XI monoclonal antibodies and methods of use thereof (2020-03-03),

6. 10221247 - Antibodies capable of binding to the coagulation factor XIa and uses thereof (2019-03-05),

7. 10137177 - Methods and compositions used in treating inflammatory and autoimmune diseases (2018-11-27),

8. 10040866 - Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof (2018-08-07),

9. 9783614 - Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof (2017-10-10),

10. 9637550 - Anti-fXI antibodies and methods of use (2017-05-02),

11. 9636399 - Anti-factor XI monoclonal antibodies and methods of use thereof (2017-05-02),

12. 9125895 - Anti-factor XI monoclonal antibodies and methods of use thereof (2015-09-08),

13. 8940883 - Anti-fXI antibodies and methods of use (2015-01-27),

14. 8399648 - Polynucleotides encoding anti-factor XI monoclonal antibodies and methods of use thereof (2013-03-19),

15. 8388959 - Anti-fXI antibodies and methods of use (2013-03-05),

Title: The Innovative Journey of Erik Tucker: Pioneering Antibody Inventions

Introduction: Erik Tucker, a prolific inventor based in Portland, Oregon, has made significant contributions to the field of biomedicine through his groundbreaking work in developing antibodies for inhibiting thrombosis while preserving hemostasis.

Latest Patents: Erik Tucker's latest patents include "Antibodies capable of binding to the coagulation factor XIa and uses thereof" and "Antibodies against factor XI and uses thereof." These inventions focus on novel binding molecules, particularly antibodies, that target Factor XI to inhibit thrombus formation effectively.

Career Highlights: With an impressive total of 14 patents to his name, Erik Tucker has demonstrated his expertise in the field of biotechnology. He has notably been associated with renowned institutions such as Oregon Health & Science University and Vanderbilt University, where his innovative research has paved the way for advancements in thrombosis-related treatment.

Collaborations: Throughout his career, Erik Tucker has collaborated with esteemed peers such as Andras Gruber and David Gailani. Together, they have synergized their skills and knowledge to push the boundaries of antibody technology, leading to the development of impactful solutions for combating thrombosis.

Conclusion: Erik Tucker's inventive spirit and dedication to improving healthcare outcomes shine through his remarkable portfolio of patents. His visionary work in the realm of antibody innovations underscores his commitment to addressing critical medical challenges, and his collaborations have further enriched the field of biomedicine. Erik Tucker stands as a true trailblazer in the journey towards enhancing patient care and advancing medical research.

Profile summary based on public USPTO records.